Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 616K
2: EX-10.12 Material Contract HTML 41K
3: EX-10.23 Material Contract HTML 29K
4: EX-21 Subsidiaries List HTML 18K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
15: R1 Document And Entity Information HTML 48K
16: R2 Consolidated Balance Sheets HTML 102K
17: R3 Consolidated Balance Sheets (Parentheticals) HTML 32K
18: R4 Consolidated Statements of Comprehensive Loss HTML 59K
19: R5 Consolidated Statements of Stockholders' Equity HTML 62K
(Deficit)
20: R6 Consolidated Statements of Stockholders' Equity HTML 28K
(Deficit) (Parentheticals)
21: R7 Consolidated Statements of Cash Flows HTML 95K
22: R8 Note 1 - Organization and Summary of Significant HTML 87K
Accounting Policies
23: R9 Note 2 Inventory HTML 23K
24: R10 Note 3 - Trademark and Patents HTML 31K
25: R11 Note 4 - Accounts Payable - Related Parties HTML 23K
26: R12 Note 5 - Accrued Expenses HTML 29K
27: R13 Note 6 - Accrued Expenses - Related Parties HTML 29K
28: R14 Note 7 - Notes Payable HTML 38K
29: R15 Note 8 - Notes Payable - Related Parties HTML 24K
30: R16 Note 9 - Warrant Liability HTML 33K
31: R17 Note 10 - Commitments and Contingencies HTML 40K
32: R18 Note 11 - Equity Transactions HTML 65K
33: R19 Note 12 - Going Concern HTML 27K
34: R20 Note 13 - Subsequent Events HTML 29K
35: R21 Accounting Policies, by Policy (Policies) HTML 132K
36: R22 Note 1 - Organization and Summary of Significant HTML 54K
Accounting Policies (Tables)
37: R23 Note 3 - Trademark and Patents (Tables) HTML 31K
38: R24 Note 5 - Accrued Expenses (Tables) HTML 28K
39: R25 Note 6 - Accrued Expenses - Related Parties HTML 28K
(Tables)
40: R26 Note 7 - Notes Payable (Tables) HTML 37K
41: R27 Note 9 - Warrant Liability (Tables) HTML 31K
42: R28 Note 11 - Equity Transactions (Tables) HTML 58K
43: R29 Note 1 - Organization and Summary of Significant HTML 52K
Accounting Policies (Details)
44: R30 Note 1 - Organization and Summary of Significant HTML 29K
Accounting Policies (Details) - Schedule of
Earnings Per Share, Basic and Diluted
45: R31 Note 1 - Organization and Summary of Significant HTML 31K
Accounting Policies (Details) - Schedule of
Deferred Tax Assets and Liabilities
46: R32 Note 1 - Organization and Summary of Significant HTML 35K
Accounting Policies (Details) - Schedule of
Effective Income Tax Rate Reconciliation
47: R33 Note 1 - Organization and Summary of Significant HTML 24K
Accounting Policies (Details) - Schedule of
Effective Income Tax Rate Reconciliation
(Parentheticals)
48: R34 Note 2 Inventory (Details) HTML 23K
49: R35 Note 3 - Trademark and Patents (Details) HTML 38K
50: R36 Note 3 - Trademark and Patents (Details) - HTML 32K
Schedule of Finite-Lived Intangible Assets
51: R37 Note 4 - Accounts Payable - Related Parties HTML 29K
(Details)
52: R38 NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of HTML 29K
Accrued Liabilities
53: R39 Note 6 - Accrued Expenses - Related Parties HTML 24K
(Details)
54: R40 Note 6 - Accrued Expenses - Related Parties HTML 28K
(Details) - Schedule of Accrued Liabilities
55: R41 NOTE 7 - NOTES PAYABLE (Details) - Schedule of HTML 41K
Debt
56: R42 Note 7 - Notes Payable (Details) - Schedule of HTML 73K
Debt (Parentheticals)
57: R43 Note 8 - Notes Payable - Related Parties (Details) HTML 41K
58: R44 Note 9 - Warrant Liability (Details) HTML 32K
59: R45 Note 9 - Warrant Liability (Details) - Fair Value HTML 31K
Measurements, Recurring and Nonrecurring,
Valuation Techniques
60: R46 Note 10 - Commitments and Contingencies (Details) HTML 158K
61: R47 Note 11 - Equity Transactions (Details) HTML 115K
62: R48 Note 11 - Equity Transactions (Details) - Schedule HTML 35K
of Share-based Payment Award, Stock Options,
Valuation Assumptions
63: R49 Note 11 - Equity Transactions (Details) - Schedule HTML 54K
of Stock Options Roll Forward
64: R50 Note 11 - Equity Transactions (Details) - HTML 44K
Share-based Compensation, Stock Options, Activity
65: R51 Note 12 - Going Concern (Details) HTML 47K
66: R52 Note 13 - Subsequent Events (Details) HTML 67K
68: XML IDEA XML File -- Filing Summary XML 120K
67: EXCEL IDEA Workbook of Financial Reports XLSX 66K
9: EX-101.INS XBRL Instance -- mzei-20171231 XML 809K
11: EX-101.CAL XBRL Calculations -- mzei-20171231_cal XML 100K
12: EX-101.DEF XBRL Definitions -- mzei-20171231_def XML 692K
13: EX-101.LAB XBRL Labels -- mzei-20171231_lab XML 807K
14: EX-101.PRE XBRL Presentations -- mzei-20171231_pre XML 656K
10: EX-101.SCH XBRL Schema -- mzei-20171231 XSD 137K
69: ZIP XBRL Zipped Folder -- 0001185185-18-000468-xbrl Zip 115K
‘EX-32.2’ — Certification — §906 – SOA’02
This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I,
Stephanie L. Sorensen, Chief Financial Officer of Medizone International, Inc. (the
“Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
(1) The accompanying Annual Report on Form 10-K of the Company for the year ended December 31, 2017 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial and Accounting Officer)
|
|
A signed original of this written statement required by Section 906 has been provided to
the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be
incorporated by reference into any filing of Medizone International, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
